MDMarie Darby

Marie Darby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marie Darby has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • [36-OR]

    by Jessica L. Faulkner, Marie M. Darby, Denise C. Cornelius, Ashlyn C. Harmon, Lorena M. Amaral, Janae Moseley, Florian Herse, Gerd Wallukat, Ralf Dechend, Babbette LaMarca


  • Maternal Hemodynamics by Thoracic Impedance Cardiography for Normal Pregnancy and the Postpartum Period

    by Rachael Morris, Imran Mbbs Sunesara, Laura Rush, Belinda Anderson, Pamela G. Rn Blake, Marie Darby, Sandip Sawardecker, Sarah Novotny, James A. Bofill, James N. Jr Martin

    OBJECTIVE: To establish normative impedance cardiography values for the second half of pregnancy and up to 48 hours postpartum after either vaginal or cesarean delivery. METHODS: A single-center prospective observational institutional review board-approved study of normotensive women (n=168) using thoracic impedance cardiography performed at specific times during gestation. Antepartum testing was performed at three time periods: 20–27 weeks, 28–33 weeks, and 34–40 weeks of gestation. Postpartum testing was undertaken after the immediate puerperium at 6–23 hours and 24–48 hours after vaginal or cesarean delivery. Data analysis was performed using STATA software; data are expressed as mean±standard deviation. RESULTS: All seven of the patient groups studied were comparable with regard to demographic features; 80% of the study participants were African American. Group means obtained between 20 and 40 weeks of gestation and postpartum after vaginal and cesarean delivery fell within the “normal range” of the hemodynamic graph that was developed to associate mean arterial pressure and systemic vascular resistance. The thoracic fluid content group means in both vaginal and cesarean delivery groups were higher than the antepartum patient groups. The thoracic fluid content mean after cesarean delivery at 48 hours is significantly higher than the mean value recorded between 20 and 27 weeks of gestation (P<.05). The systemic vascular resistance systemic vascular resistance means in each of the postpartum groups were significantly higher than the late second-trimester group means recorded at 20–27 weeks of gestation (P<.05). CONCLUSION: The normative values reported in this investigation can be used to interpret and assess similarly tested patients with hypertensive or otherwise complicated pregnancy. LEVEL OF EVIDENCE: III


    • 23 September 2013
      • Vol. 1  (2)

    Vitamin D Supplementation Suppresses Hypoxia-Stimulated Placental Cytokine Secretion, Hypertension and CD4+ T Cell Stimulation in Response to Placental Ischemia

    by Marie M Darby, Kedra Wallace, Denise Cornelius, Krystal T Chatman, Janae N Mosely, James N Martin, Christine A Purser, Rodney C Baker, Michelle T Owens, B Babbette Lamarca

    To investigate a role of Vitamin D in the pathogenesis of preeclampsia (PE), and to discern any potential benefits of Vitamin D supplementation on hypertension in the RUPP rat model of PE. Blood and placentas from normal pregnancies (NP) and PE were collected following elective cesarean delivery without evidence of infection. Circulating Vitamin D was extracted by HPLC and measured via mass spectrometry. Media for placenta explants was supplemented with Vitamin D and exposed to hypoxic (1% O2) or normoxic (6% O2) conditions for 24 hours. ELISAs were performed on media and normalized to total protein to determine cytokine secretion. RUPP rats were supplemented with vitamin D by oral gavage, and blood pressure (MAP) and pup weights were measured in NP and RUPP rats with or without Vitamin D supplementation. Flow cytometry was used to evaluate CD4+ Tcells in control RUPP rats and RUPP rats treated with Vitamin D. Inflammatory cytokine secretion was higher (p<0.05) while the anti-inflammatory cytokine, IL-10, was significantly lower in the media of PE placentas compared to NP (p=0.005). Vitamin D supplementation decreased hypoxia stimulated pro-inflammatory cytokine secretion (p=0.003) in the media of PE placentas. Vitamin D decreased MAP and circulating CD4+ T cells in the RUPP rat model of PE (p<0.05). Vitamin D supplementation may be useful in the treatment or prevention of hypertensive disorders in pregnancy.


  • A complicated role for the renin–angiotensin system during pregnancy: highlighting the importance of drug discovery

    by Marie Darby, James N Martin, Babbette LaMarca

    Introduction: Blood pressure management is recommended to avoid maternal cerebrovascular or cardiovascular compromise during pregnancy. Current antihypertensive treatment during pregnancy with positive safety profiles includes labetalol, hydralazine, methyldopa and nifedipine. Areas covered: Many earlier animal and human studies indicate that angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are associated with fetopathy; therefore, these drugs are contraindicated during pregnancy, especially if these medications were taken during the second and third trimesters. The role of the RAS is quite complex, with fetal development heavily dependent on its appropriate expression and function. New findings indicate that the placental unit expresses its own RAS in order to regulate angiogenesis. Multiple studies have shown that women with abnormal uterine doppler sonography produce an agonistic autoantibody to the angiotensin I receptor, implicating a role for RAS function and regulation in abnormal pregnancies. Importantly, interruption of a normal RAS compromises fetal development. Expert opinion: Traditional medications that inhibit components of RAS for long-term hypertension control are not appropriate for use before or during pregnancy. Further study and drug discovery are needed to find alternative pathways for treatment of hypertensive disorders when pregnancy is present or a possibility.


  • Using case reports to determine when liver bleeding occurs during disease progression in HELLP syndrome

    by Marie Darby, James N. Martin, Sarah Q. Mitchell, Michelle Y. Owens, Kedra Wallace

    Background: Hepatic hemorrhage occurs in less than 5% of patients with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome but it is a profound cause of maternal/perinatal morbidity and mortality.Objectives: To determine when liver bleeding occurs during the development of HELLP syndrome.Search strategy: The English literature was searched for all reports of HELLP syndrome associated with liver bleeding.Selection criteria: Eighty‐seven case summaries of liver bleeding in the setting of HELLP syndrome were included. The standard definition of HELLP syndrome was used with expansion into the Mississippi classification system, supplemented by patients with partial HELLP syndrome.Data collection and analysis: Demographic and clinical data were collected and recorded in an Excel database.Main results: Liver bleeding was detected in 18 (20.7%) patients with class 1 HELLP syndrome, 24 (27.6%) with class 2 HELLP syndrome, and 12 (13.8%) with class 3 or partial HELLP syndrome. In 33 (37.9%) patients, the exact class of HELLP syndrome at the time liver bleeding was detected could not be determined from the published descriptions.Conclusions: Liver bleeding can occur early during HELLP syndrome development, not only in patients with advanced, class 1 illness.